

ADOPTED BY COMMITTEE: Jan 2, 2026

INITIAL QUALIFYING CONDITIONS

Whereas, the Medical Psilocybin Act, codified at NMSA 1978, Section 26-2D-3(I), establishes four initial qualifying conditions for participation in the Medical Psilocybin Program: Post-Traumatic Stress Disorder, Substance Use Disorders, end-of-life–related distress, and Treatment-Resistant Depression; and

Whereas, standard practice within the United States healthcare system for clinical documentation, billing, quality measurement, utilization review, and public health surveillance is the use of International Classification of Diseases, Tenth Revision (ICD-10) diagnostic codes; and

Whereas, the use of ICD-10 codes promotes consistency, clarity, interoperability, and data integrity across healthcare providers, regulators, and public health entities;

Therefore, be it resolved, that the Patient Qualification & Safety Committee, acting in its advisory capacity, defines the qualifying conditions established in the Medical Psilocybin Act using the ICD-10 diagnostic framework as set forth in the table below.

Legislative Condition NMSA1978, § 26-2D-3I	Medical Condition	ICD-10 Code or subsequent codes
Treatment-Resistant Depression	Major Depressive Disorder, recurrent, meeting criteria for treatment resistance, defined as failure of two or more adequate trials of antidepressant medications	(F33.1 or F33.2) and documented failure of ≥2 antidepressants
Post-Traumatic Stress Disorder	Post-Traumatic Stress Disorder	F43.12
Substance Use Disorders	Substance dependence, including but not limited to alcohol, opioids, cannabis, sedatives/hypnotics/anxiolytics, stimulants, inhalants, and other psychoactive substances	F10.2, F11.2, F12.2, F13.2, F14.2, F15.2, F17.2, F18.2, F19.2
End-of-life–related distress	Palliative care status associated with serious or life-limiting illness	Z51.5